What is lutetium PSMA therapy?

What is lutetium PSMA therapy?

You may be offered lutetium-177 PSMA therapy (lutetium PSMA), or Prostate-Specific Membrane Antigen therapy if you have advanced prostate cancer. It’s a type of Peptide Receptor Radionuclide Therapy (PRRT).

Lutetium PSMA therapy aims to improve your symptoms and reduce the size of your tumours. It can also slow their growth. Afterwards, some people experience a long period of remission, but it doesn’t cure your cancer.

It’s used when cancer has metastasised (spread). It can help when other treatments have failed, are causing significant harm or side-effects.

How does lutetium PSMA therapy work?

PSMA is a type of protein found on the surface of a cell. It’s located on the prostate gland, some tumours, and normal tissues.

If you have prostate cancer, you’ll have more PSMA than normal. If the prostate cancer has spread to other parts of the body (metastasised), the PSMA will also be there.

Lutetium-177 PSMA therapy uses a molecule which attaches itself to the PSMA receptors on the cancer cells.

Before it’s given to you, the PSMA molecule is bound with lutetium-177. This is a radioactive substance that damages and destroys the prostate cancer cells in a targeted way.

The PSMA molecule transports the lutetium-177 direct to the tumour site. That means the rest of your body isn’t exposed to radiation.

Further information

Make an enquiry

Contact us today to find out how GenesisCare can help you.

Find a centre near you

Read next